Leqembi, the Alzheimer’s drug from Eisai and Biogen, has recently received the Food and Drug Administration’s (FDA) approval. Subsequently, Twitter influencer conversations around Leqembi witnessed a significant spurt, reveals the Social Media Analytics Platform of GlobalData, a leading data and analytics company.

Shreyasee Majumder, Social Media Analyst at GlobalData, comments: “Influencers in the pharmaceutical business gave mixed opinions regarding the FDA’s authorization because they agree with the fact that the medication may reduce cognitive deterioration, but it cannot be considered as a curable drug. Leqembi’s effectiveness, pricing, and threat factors (side effects) in comparison to those of other Alzheimer’s medications are being broadly discussed, which depicts negative influencer sentiment towards the drug.”

Below are a few of the most popular influencer opinions captured by the GlobalData’s Social Media Analytics Platform:

  1. Rob Swanda, Senior Engineer, TLDP at BD:

“Happy Friday with fantastic news in the fight against Alzheimer’s disease! The US FDA has approved Leqembi, a monoclonal antibody treatment, for the reduction of amyloid beta plaques in patients with mild cognitive impairment or mild dementia.”

  1. Eric Widera, Professor of Medicine at UC San Francisco:

“Leqembi (lecanemab) is now approved through the standard FDA approval pathway. No REMS but CMS looking like they will mandate registry participation for reimbursement (for a drug with high risk and poor evidence in diverse populations seems reasonable)”

  1. Ian Kremer, Executive Director at LEAD Coalition:

“The @US_FDA traditional approval of #Leqembi is a watershed moment for our community and the best news in my 26+ years of #Alzheimers advocacy. Deepest #gratitude to study participants, @EisaiUS, and all others devoted to making #dementia only a memory. ”

  1. Elin Silveous, Health Advocate:

“Leqembi is not a cure for Alzheimer’s, and the drug doesn’t improve patients’ memories or cognitive abilities. It also does not stop the disease from getting worse. #InformedDecisions”

  1. Dale Bredesen, Professor and Founding President, Buck Institute for Age Research:

“The Alzheimer’s Association is lobbying for Medicare coverage of Leqembi (lecanemab) and other ineffective drugs. No drug has ever sustainably improved cognition, and Leqembi comes with a large price tag and serious side effects.”